keyword
Keywords Bisphosphonate use for osteopo...

Bisphosphonate use for osteoporosis in children with ALL

https://read.qxmd.com/read/38165327/bisphosphonates-in-glucocorticoid-treated-patients-with-duchenne-muscular-dystrophy
#1
JOURNAL ARTICLE
Erik Landfeldt, Kim Phung, Farasat Zaman, Eva Åström, Sophia Abner, Hanns Lochmüller, Thomas Sejersen, Leanne M Ward
BACKGROUND AND OBJECTIVES: Bisphosphonates are routinely used to treat osteoporosis in patients with Duchenne muscular dystrophy (DMD), a rare, severely debilitating neuromuscular disease. We sought to synthesize and grade benefits and harms evidence of bisphosphonates in glucocorticoid-treated patients with DMD. METHODS: In this systematic review (PROSPERO identifier: CRD42020157606), we searched MEDLINE, CINAHL, Embase, PsycINFO, Web of Science, and CENTRAL for articles published from inception up to and including March 31, 2023, reporting results in any language from any study type...
January 23, 2024: Neurology
https://read.qxmd.com/read/38136063/bone-fracture-in-rett-syndrome-mechanisms-and-prevention-strategies
#2
REVIEW
Carla Caffarelli, Antonella Al Refaie, Caterina Mondillo, Michela De Vita, Leonardo Baldassini, Giuseppe Valacchi, Stefano Gonnelli
The present study aimed to evaluate the burden and management of fragility fractures in subjects with Rett syndrome. We searched all relevant medical literature from 1 January 1986 to 30 June 2023 for studies under the search term "Rett syndrome and fracture". The fracture frequency ranges from a minimum of 13.9% to a maximum of 36.1%. The majority of such fractures occur in lower limb bones and are associated with low bone mineral density. Anticonvulsant use, joint contractures, immobilization, low physical activity, poor nutrition, the genotype, and lower calcium and vitamin D intakes all significantly impair skeletal maturation and bone mass accrual in Rett syndrome patients, making them more susceptible to fragility fractures...
November 27, 2023: Children
https://read.qxmd.com/read/37681243/electrocardiogram-changes-following-intravenous-bisphosphonate-infusion-a-systematic-review-and-meta-analysis
#3
JOURNAL ARTICLE
Alex Shoung, Nicholas Shoung, Rachael Hii, Nitesh Nerlekar, Peter R Ebeling, Alexander J Rodríguez
Bisphosphonates are first-line treatments for several bone and mineral disorders. Studies have reported an increased incidence of serious atrial fibrillation in patients receiving bisphosphonates; however, uncertainty remains as to whether electrical disturbances are precipitated by bisphosphonates. We aimed to review the literature for studies reporting electrocardiogram (ECG) findings in patients receiving intravenous bisphosphonates for any indication. We searched MEDLINE and EMBASE from inception until January 14, 2023, for studies reporting ECG parameters after intravenous bisphosphonate infusion...
November 2023: Journal of Bone and Mineral Research
https://read.qxmd.com/read/37296804/forestalling-hungry-bone-syndrome-after-parathyroidectomy-in-patients-with-primary-and-renal-hyperparathyroidism
#4
REVIEW
Mara Carsote, Claudiu Nistor
UNLABELLED: Hungry bone syndrome (HBS), severe hypocalcemia following parathyroidectomy (PTX) due to rapid drop of PTH (parathormone) after a previous long term elevated concentration in primary (PHPT) or renal hyperparathyroidism (RHPT), impairs the outcome of underlying parathyroid disease. OBJECTIVE: overview HBS following PTx according to a dual perspective: pre- and post-operative outcome in PHPT and RHPT. This is a case- and study-based narrative review. INCLUSION CRITERIA: key research words "hungry bone syndrome" and "parathyroidectomy"; PubMed access; in extenso articles; publication timeline from Inception to April 2023...
June 2, 2023: Diagnostics
https://read.qxmd.com/read/37159055/treatment-for-osteoporosis-in-people-with-beta-thalassaemia
#5
REVIEW
Amit Bhardwaj, Kye Mon Min Swe, Nirmal K Sinha
BACKGROUND: Osteoporosis is characterized by low bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility. In people with beta-thalassaemia, osteoporosis represents an important cause of morbidity and is due to a number of factors. First, ineffective erythropoiesis causes bone marrow expansion, leading to reduced trabecular bone tissue with cortical thinning. Second, excessive iron loading causes endocrine dysfunction, leading to increased bone turnover...
May 9, 2023: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/36835951/medication-related-osteonecrosis-of-the-jaws-mronj-in-children-and-young-patients-a-systematic-review
#6
REVIEW
Hemil Dario Rosales, Henry Garcia Guevara, Stefania Requejo, Maria Dianella Jensen, Julio Acero, Sergio Olate
Medication-related osteonecrosis of the jaw (MRONJ) is defined by the American Association of Oral and Maxillofacial Surgeons (AAOMS) as the presence of an exposed bone area in the maxillofacial region, present for more than eight weeks in patients treated with the use of antiresorptive or antiangiogenic agents, with no history of radiation or metastatic disease. Bisphosphonates (BF) and denosumab (DS) are widely used in adults for the management of patients with cancer and osteoporosis, and recently there has been an increase in their use in child and young patients for the management of disorders such as osteogenesis imperfecta (OI), glucocorticoid-induced osteoporosis, McCune-Albright syndrome (MAS), malignant hypercalcemia, and others...
February 10, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/36625789/bisphosphonates-for-osteoporosis-in-people-with-cystic-fibrosis
#7
REVIEW
Tomas C Jeffery, Anne B Chang, Louise S Conwell
BACKGROUND: Osteoporosis is a disorder of bone mineralisation occurring in about one third of adults with cystic fibrosis. Bisphosphonates can increase bone mineral density and decrease the risk of new fractures in post-menopausal women and people receiving long-term oral corticosteroids. This is an updated version of a previous review. OBJECTIVES: To assess the effects of bisphosphonates on the frequency of fractures, bone mineral density, quality of life, adverse events, trial withdrawals, and survival in people with cystic fibrosis...
January 10, 2023: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/34224134/bisphosphonate-use-in-children-with-cerebral-palsy
#8
JOURNAL ARTICLE
Tim Hurley, Zunera Zareen, Philip Stewart, Ciara McDonnell, Denise McDonald, Eleanor Molloy
BACKGROUND: Cerebral palsy (CP) is a heterogeneous group of non-progressive disorders of posture or movement, caused by a lesion of the developing brain. Osteoporosis is common in children with cerebral palsy, particularly in children with reduced gross motor function, and leads to an increased risk of fractures. Gross motor function in children with CP can be categorised using a tool called the Gross Motor Function Classification System (GMFCS). Bisphosphonate increases bone mineral density (BMD) and reduces fracture rates...
July 5, 2021: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/33825940/a-quality-improvement-project-to-address-the-challenges-surrounding-zoledronic-acid-use-in-children
#9
JOURNAL ARTICLE
David R Weber, Maria Cristina Gil Diaz, Silvia Louis, Noya Rackovsky, Roman Rahmani, Sierra D Stauber
INTRODUCTION: Zoledronic acid (ZA) is an intravenous bisphosphonate used to treat pediatric osteoporosis. Adverse events including hypocalcemia and acute phase reaction (APR) are common following first-infusion. The purpose of this report is to describe implementation of a ZA clinical practice guideline and the subsequent process changes to improve adherence to aspects of the protocol related to safety and efficacy. METHODS: Quality assurance was evaluated by chart review over a 5-year period to compare the prevalence of hypocalcemia and APR to published data...
July 2021: Journal of Bone and Mineral Metabolism
https://read.qxmd.com/read/33128074/methotrexate-osteopathy-five-cases-and-systematic-literature-review
#10
REVIEW
F Robin, S Cadiou, J-D Albert, G Bart, G Coiffier, P Guggenbuhl
INTRODUCTION: Methotrexate (MTX)-related osteopathy is rare, defined by the triad of pain, osteoporosis, and "atypical fractures" when it was first described in the 1970s in children treated with high doses MTX for acute leukemia. Since then, several cases have been reported in patients treated with low-dose MTX for inflammatory diseases. METHODS: A systematic research of cases of MTX-related osteopathy was performed in records of Rheumatology Department of Rennes University Hospital...
October 30, 2020: Osteoporosis International
https://read.qxmd.com/read/31533771/individualized-treatment-with-denosumab-in-children-with-osteogenesis-imperfecta-follow-up-of-a-trial-cohort
#11
JOURNAL ARTICLE
Heike Hoyer-Kuhn, Mirko Rehberg, Christian Netzer, Eckhard Schoenau, Oliver Semler
BACKGROUND: Osteogenesis imperfecta (OI) is a rare disease leading to hereditary bone fragility. Nearly 90% of cases are caused by mutations in the collagen genes COL1A1/A2 (classical OI) leading to multiple fractures, scoliosis, short stature and nonskeletal findings as blue sclera, hypermobility of joints, bone pain and delayed motor function development. Bisphosphonates are used in most moderate and severely affected patients assuming that an increase of bone mineral density might reduce fractures and bone pain in patients with OI...
September 18, 2019: Orphanet Journal of Rare Diseases
https://read.qxmd.com/read/31447218/can-children-be-affected-by-bisphosphonate-related-osteonecrosis-of-the-jaw-a-systematic-review
#12
JOURNAL ARTICLE
Nathália Tuany Duarte, Bruna de Oliveira Rech, Isabela Godoy Martins, Juliana Bertoldi Franco, Karem Lopez Ortega
Knowledge of bisphosphonate-related osteonecrosis of the jaw (BRONJ) is mostly based on adult cases, however bisphosphonates are also currently recommended for different paediatric diseases resulting in osteoporosis. The aim of this study was to review the literature on the risk of developing BRONJ in children and adolescents. The PubMed, LILACS, Web of Science, Scopus, and Cochrane databases were searched using the key words "bisphosphonates", "osteonecrosis", "jaw", and "children". Literature reviews, case reports, abstracts, theses, textbooks, and book chapters were excluded...
February 2020: International Journal of Oral and Maxillofacial Surgery
https://read.qxmd.com/read/30616029/outcomes-following-intravenous-bisphosphonate-infusion-in-pediatric-patients-a-7-year-retrospective-chart-review
#13
JOURNAL ARTICLE
Nat Nasomyont, Lindsey N Hornung, Catherine M Gordon, Halley Wasserman
INTRODUCTION: Intravenous bisphosphonates (IV BP) have been used to treat children with osteoporosis for many years. Favorable side effect profile and improvements in bone mineral density (BMD) have been demonstrated in patients with osteogenesis imperfecta (OI), a primary form of osteoporosis in pediatrics. Less is known about the safety of IV BP in children with secondary osteoporosis or glucocorticoid-induced osteoporosis (GIO). We aimed to determine the prevalence of both acute and long-term side effects and assess the efficacy of IV BP treatment to increase bone mineral density in pediatric patients with varying presentations of compromised bone health...
April 2019: Bone
https://read.qxmd.com/read/29504223/consensus-guidelines-on-the-use-of-bisphosphonate-therapy-in-children-and-adolescents
#14
JOURNAL ARTICLE
Peter J Simm, Andrew Biggin, Margaret R Zacharin, Christine P Rodda, Elaine Tham, Aris Siafarikas, Craig Jefferies, Paul L Hofman, Diane E Jensen, Helen Woodhead, Justin Brown, Benjamin J Wheeler, Denise Brookes, Antony Lafferty, Craig F Munns
Bisphosphonate therapy is the mainstay of pharmacological intervention in young people with skeletal fragility. The evidence of its use in a variety of conditions remains limited despite over three decades of clinical experience. On behalf of the Australasian Paediatric Endocrine Group, this evidence-based consensus guideline presents recommendations and discusses the graded evidence (using the GRADE system) for these recommendations. Primary bone fragility disorders such as osteogenesis imperfecta are considered separately from osteoporosis secondary to other clinical conditions (such as cerebral palsy, Duchenne muscular dystrophy)...
March 2018: Journal of Paediatrics and Child Health
https://read.qxmd.com/read/28117876/interventions-to-prevent-and-treat-corticosteroid-induced-osteoporosis-and-prevent-osteoporotic-fractures-in-duchenne-muscular-dystrophy
#15
REVIEW
Jennifer M Bell, Michael D Shields, Janet Watters, Alistair Hamilton, Timothy Beringer, Mark Elliott, Rosaline Quinlivan, Sandya Tirupathi, Bronagh Blackwood
BACKGROUND: Corticosteroid treatment is considered the 'gold standard' for Duchenne muscular dystrophy (DMD); however, it is also known to induce osteoporosis and thus increase the risk of vertebral fragility fractures. Good practice in the care of those with DMD requires prevention of these adverse effects. Treatments to increase bone mineral density include bisphosphonates and vitamin D and calcium supplements, and in adolescents with pubertal delay, testosterone. Bone health management is an important part of lifelong care for patients with DMD...
January 24, 2017: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/26999874/bone-health-in-adolescence
#16
REVIEW
Dennis E Carey, Neville H Golden
Osteoporosis occurs during childhood and adolescence as a heritable condition such as OI, with acquired disease (eg, IBD), or iatrogenically as a result of high-dose glucocorticoid therapy. However, the number of children affected by osteoporosis during youth is small compared to the numbers who will develop osteoporosis in adulthood. Prevention of adult osteoporosis requires that an optimal environment for the achievement of peak bone mass be established during the growing years. Detection of low BMD can be achieved using modalities such as DXA and pQCT...
August 2015: Adolescent Medicine: State of the Art Reviews
https://read.qxmd.com/read/26964506/treatment-for-osteoporosis-in-people-with-%C3%A3-thalassaemia
#17
REVIEW
Amit Bhardwaj, Kye Mon Min Swe, Nirmal K Sinha, Ifeyinwa Osunkwo
BACKGROUND: Osteoporosis is a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to fracture. Osteoporosis represents an important cause of morbidity in people with beta-thalassaemia and its pathogenesis is multifactorial. Factors include bone marrow expansion due to ineffective erythropoiesis, resulting in reduced trabecular bone tissue with cortical thinning; endocrine dysfunction secondary to excessive iron loading, leading to increased bone turnover; and lastly, a predisposition to physical inactivity due to disease complications with a subsequent reduction in optimal bone mineralization...
March 10, 2016: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/25096864/bisphosphonate-use-in-children-with-pediatric-osteoporosis-and-other-bone-conditions
#18
REVIEW
Elizabeth A Szalay
Bisphosphonates (BPs) are used most commonly in children with osteogenesis imperfecta, resulting in increased trabeculae and cortical thickness, increased bone density as measured by DXA (Dual Energy X-ray Absorptiometry), and improved vertebral morphology. Less well documented in controlled trials are decrease in long bone fractures, improved strength and motor function, and decreased pain. Outside of children with osteogenesis imperfecta, use of bisphosphonates in children is increasing, all of which is off-label...
2014: Journal of Pediatric Rehabilitation Medicine
https://read.qxmd.com/read/23826578/efficacy-of-pamidronate-in-children-with-low-bone-mineral-density-during-and-after-chemotherapy-for-acute-lymphoblastic-leukemia-and-non-hodgkin-lymphoma
#19
JOURNAL ARTICLE
Jae Min Lee, Ji Eun Kim, Soon Hwan Bae, Jeong Ok Hah
BACKGROUND: Reduced bone mineral density (BMD) is a significant sequelae in children receiving chemotherapy for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Reduced BMD is associated with an increased risk for fractures. Pamidronate, a second-generation bisphosphonate, has been used to treat osteoporosis in children. This study evaluated the safety and efficacy of pamidronate in children with low BMD during and after chemotherapy for ALL and NHL. METHODS: Between April 2007 and October 2011, 24 children with ALL and NHL were treated with pamidronate...
June 2013: Blood Research
https://read.qxmd.com/read/20346254/effectiveness-of-the-treatment-with-intravenous-pamidronate-in-calcinosis-in-juvenile-dermatomyositis
#20
JOURNAL ARTICLE
A Marco Puche, I Calvo Penades, B Lopez Montesinos
OBJECTIVE: Calcinosis is a frequent finding in up to 40% of children with juvenile dermatomyositis (JDM). Different treatments (aluminum hydroxide, diltiazem, probenecid, alendronate, etc.) have been used in an attempt to clear calcinosis and to avoid the onset of new calcium deposition, but none has been clearly effective. Pamidronate is a nitrogen-containing bisphosphonate with a potent inhibiting bone resorption effect that has been used to treat osteoporosis in children. We report three children with JDM who developed calcinosis and who received intravenous pamidronate with good results...
January 2010: Clinical and Experimental Rheumatology
keyword
keyword
4483
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.